Investigation of FGFR2-IIIC Signaling Via FGF-2 Ligand for Advancing GCT Stromal Cell Differentiation

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2012 Oct 17

PMID 23071632

Citations 7

Authors

Shalini Singh

Mohini Singh

Isabella W Y Mak

Robert Turcotte

Michelle Ghert

Affiliations

Soon will be listed here.

Abstract

Giant cell tumor of bone (GCT) is an aggressive bone tumor consisting of multinucleated osteoclast-like giant cells and proliferating osteoblast-like stromal cells. The signaling mechanism involved in GCT stromal cell osteoblastic differentiation is not fully understood. Previous work in our lab reported that GCT stromal cells express high levels of TWIST1, a master transcription factor in skeletal development, which in turn down-regulates Runx2 expression and prevents terminal osteoblastic differentiation in these cells. The purpose of this study was to determine the upstream regulation of TWIST1 in GCT cells. Using GCT stromal cells obtained from patient specimens, we demonstrated that fibroblast growth factor receptor (FGFR)-2 signaling plays an essential role in bone development and promotes differentiation of immature osteoblastic cells. Fibroblast growth factor (FGF)-2 stimulates FGFR-2 expression, resulting in decreased TWIST1 expression and increased Runx2, alkaline phosphastase (ALP) and osteopontin (OPN) expression. Inhibition of FGFR-2 through siRNA decreased the expression of ALP, Runx2 and OPN in GCT stromal cells. Our study also confirmed that FGF-2 ligand activates downstream ERK1/2 signaling and pharmacological inhibition of the ERK1/2 signaling pathway suppresses FGF-2 stimulated osteogenic differentiation in these cells. Our results indicate a significant role of FGFR-2 signaling in osteoblastic differentiation in GCT stromal cells.

Citing Articles

Implication of the p53-Related miR-34c, -125b, and -203 in the Osteoblastic Differentiation and the Malignant Transformation of Bone Sarcomas.

Jacques C, Tesfaye R, Lavaud M, Georges S, Baudhuin M, Lamoureux F Cells. 2020; 9(4).

PMID: 32230926 PMC: 7226610. DOI: 10.3390/cells9040810.

Retraction: Investigation of FGFR2-IIIC Signaling via FGF-2 Ligand for Advancing GCT Stromal Cell Differentiation.

PLoS One. 2019; 14(7):e0220356.

PMID: 31335911 PMC: 6650062. DOI: 10.1371/journal.pone.0220356.

Identification of new genes associated to senescent and tumorigenic phenotypes in mesenchymal stem cells.

Medeiros Tavares Marques J, Cornelio D, Silbiger V, Luchessi A, de Souza S, Batistuzzo de Medeiros S Sci Rep. 2017; 7(1):17837.

PMID: 29259202 PMC: 5736717. DOI: 10.1038/s41598-017-16224-5.

The distinct clinical features of giant cell tumor of bone in pagetic and non-pagetic patients are associated with genetic, biochemical and histological differences.

Divisato G, Scotto di Carlo F, Pazzaglia L, Rizzo R, Coviello D, Benassi M Oncotarget. 2017; 8(38):63121-63131.

PMID: 28968976 PMC: 5609908. DOI: 10.18632/oncotarget.18670.

3-Dimensional micropillar drug screening identifies FGFR2-IIIC overexpression as a potential target in metastatic giant cell tumor.

Kim S, Kim J, Shin S, Kim S, Lee D, Ku B Oncotarget. 2017; 8(22):36484-36491.

PMID: 28445128 PMC: 5482670. DOI: 10.18632/oncotarget.16883.

References

Ducy P, Zhang R, Geoffroy V, Ridall A, Karsenty G . Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell. 1997; 89(5):747-54. DOI: 10.1016/s0092-8674(00)80257-3. View

Beenken A, Mohammadi M . The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov. 2009; 8(3):235-53. PMC: 3684054. DOI: 10.1038/nrd2792. View

Dailey L, Ambrosetti D, Mansukhani A, Basilico C . Mechanisms underlying differential responses to FGF signaling. Cytokine Growth Factor Rev. 2005; 16(2):233-47. DOI: 10.1016/j.cytogfr.2005.01.007. View

Lee M, Lowe G, Strong D, Wergedal J, Glackin C . TWIST, a basic helix-loop-helix transcription factor, can regulate the human osteogenic lineage. J Cell Biochem. 1999; 75(4):566-77. DOI: 10.1002/(sici)1097-4644(19991215)75:4<566::aid-jcb3>3.0.co;2-0. View

Rabinovich A, Mak I, Cowan R, Turcotte R, Colterjohn N, Singh G . Matrix Metalloproteinase Activity in the Stromal Cell of Giant Cell Tumor of Bone. Open Bone J. 2012; 1:46-52. PMC: 3266943. DOI: 10.2174/1876525400901010046. View

Ibrahimi O, Eliseenkova A, Plotnikov A, Yu K, Ornitz D, Mohammadi M . Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome. Proc Natl Acad Sci U S A. 2001; 98(13):7182-7. PMC: 34643. DOI: 10.1073/pnas.121183798. View

Ghert M, Alsaleh K, Farrokhyar F, Colterjohn N . Outcomes of an anatomically based approach to metastatic disease of the acetabulum. Clin Orthop Relat Res. 2007; 459:122-7. DOI: 10.1097/BLO.0b013e31803ea9c8. View

Lomri A, Lemonnier J, Hott M, de Parseval N, Lajeunie E, Munnich A . Increased calvaria cell differentiation and bone matrix formation induced by fibroblast growth factor receptor 2 mutations in Apert syndrome. J Clin Invest. 1998; 101(6):1310-7. PMC: 508685. View

Anderson J, Burns H, Enriquez-Harris P, Wilkie A, Heath J . Apert syndrome mutations in fibroblast growth factor receptor 2 exhibit increased affinity for FGF ligand. Hum Mol Genet. 1998; 7(9):1475-83. DOI: 10.1093/hmg/7.9.1475. View

10.

Goldring S, Schiller A, Mankin H, Dayer J, Krane S . Characterization of cells from human giant cell tumors of bone. Clin Orthop Relat Res. 1986; (204):59-75. View

11.

Kratchmarova I, Blagoev B, Haack-Sorensen M, Kassem M, Mann M . Mechanism of divergent growth factor effects in mesenchymal stem cell differentiation. Science. 2005; 308(5727):1472-7. DOI: 10.1126/science.1107627. View

12.

Komori T . Signaling networks in RUNX2-dependent bone development. J Cell Biochem. 2011; 112(3):750-5. DOI: 10.1002/jcb.22994. View

13.

Lai C, Chaudhary L, Fausto A, Halstead L, Ory D, Avioli L . Erk is essential for growth, differentiation, integrin expression, and cell function in human osteoblastic cells. J Biol Chem. 2001; 276(17):14443-50. DOI: 10.1074/jbc.M010021200. View

14.

Ornitz D . FGF signaling in the developing endochondral skeleton. Cytokine Growth Factor Rev. 2005; 16(2):205-13. PMC: 3083241. DOI: 10.1016/j.cytogfr.2005.02.003. View

15.

Mohammadi M, Honegger A, Rotin D, Fischer R, Bellot F, Li W . A tyrosine-phosphorylated carboxy-terminal peptide of the fibroblast growth factor receptor (Flg) is a binding site for the SH2 domain of phospholipase C-gamma 1. Mol Cell Biol. 1991; 11(10):5068-78. PMC: 361508. DOI: 10.1128/mcb.11.10.5068-5078.1991. View

16.

Katz E, Nyska M, Okon E, Zajicek G, ROBIN G . Growth rate analysis of lung metastases from histologically benign giant cell tumor of bone. Cancer. 1987; 59(10):1831-6. DOI: 10.1002/1097-0142(19870515)59:10<1831::aid-cncr2820591025>3.0.co;2-a. View

17.

Kobayashi T, Kronenberg H . Minireview: transcriptional regulation in development of bone. Endocrinology. 2004; 146(3):1012-7. DOI: 10.1210/en.2004-1343. View

18.

Marie P . Fibroblast growth factor signaling controlling osteoblast differentiation. Gene. 2003; 316:23-32. DOI: 10.1016/s0378-1119(03)00748-0. View

19.

Ling L, Murali S, Dombrowski C, Haupt L, Stein G, van Wijnen A . Sulfated glycosaminoglycans mediate the effects of FGF2 on the osteogenic potential of rat calvarial osteoprogenitor cells. J Cell Physiol. 2006; 209(3):811-25. DOI: 10.1002/jcp.20760. View

20.

Mansukhani A, Bellosta P, Sahni M, Basilico C . Signaling by fibroblast growth factors (FGF) and fibroblast growth factor receptor 2 (FGFR2)-activating mutations blocks mineralization and induces apoptosis in osteoblasts. J Cell Biol. 2000; 149(6):1297-308. PMC: 2175120. DOI: 10.1083/jcb.149.6.1297. View